Quick new screening could save thousands of people from bowel cancer
28 April 2010
A five-minute screening test could cut the risk of developing bowel cancer by a third and save thousands of lives from what is the UK’s second biggest cancer killer, according to new research funded by the Medical Research Council (MRC).
The new 16-year study showed that a single flexible sigmoidoscopy examination in men and women aged between 55 and 64 reduced the incidence of bowel cancer by a third, compared with a control group who had usual care. Screening with flexible sigmoidoscopy (named the ‘Flexi-Scope test’ by the research team) was particularly effective in the lower bowel, where it halved incidence of the disease.
Over the course of the study, bowel cancer mortality was reduced by 43 per cent in the group that had the Flexi-Scope test compared with the control group.
The randomised trial followed 170,432 people over an average period of 11 years, of whom 40,674 underwent a single Flexi-Scope screening.
Professor Wendy Atkin, from the Department of Surgery and Cancer at Imperial College London, who led the research said:
“Our study shows for the first time that we could dramatically reduce the incidence of bowel cancer, and the number of people dying from the disease, by using this one-off test. No other bowel cancer screening technique has ever been shown to prevent the disease.”
The Flexi-Scope test works by detecting and removing growths on the bowel wall, known as polyps, which can become cancerous if they are left untreated. Flexi-Scope is able to prevent cancer from developing by removing polyps before they become cancerous.
The new results suggest that the Flexi-Scope procedure confers long-lasting protection from developing bowel cancer. The researchers behind the study suggest that in addition to saving lives, a screening programme using Flexi-Scope could also reduce the costs associated with treating people with bowel cancer.
Research commissioned by the UK Department of Health, published in the journal Gut in 2006, suggested that if a screening programme based on this test was effective, this could save an average of £28 for every person screened.
Professor Max Parmar from the MRC which put £4 million into the study said:
"Most people are unaware that bowel cancer is one of the biggest causes of cancer deaths – only lung cancer tops it. When an MRC-funded study like this generates unprecedented results, it shows the importance of long-term research into the biggest health challenges of the day and also showcases the need for people to volunteer for clinical trials.
“This result would never have been possible without the 170,000 men and women who entered this study and it’s fantastic to have a greater proportion of men, who perhaps are not regarded as health conscious as women. As most of the NHS cancer screening tests are for women, flexi-scope presents an opportunity for men to enter screening programmes as well."
Harpal Kumar, Cancer Research UK’s chief executive, said:
“Cancer Research UK is calling on the next Government to add the test to the existing national bowel screening programme as one of its first priorities. Such a programme, backed by all UK governments, would save thousands of lives and spare tens of thousands of families the anxiety and suffering associated with a cancer diagnosis, whilst also saving the NHS money”.
About one in 20 people in the UK will develop bowel cancer during their lifetime. In the UK, it causes over 16,000 deaths each year, and is the third most common cancer. Worldwide, it accounts for more than one million cases and 600,000 deaths each year. Around nine in ten cases of bowel cancer occur in people aged 55 and above.
The current screening method for bowel cancer, called the faecal occult blood test, looks for traces of blood in stools and helps to detect cancer at an early stage. Routine screening using the faecal occult blood test is offered every two years for older people. This method of screening has been shown to reduce mortality from colorectal cancer by 25 per cent in people who use the test, but it has not been shown to reduce the risk of developing cancer.
This study was carried out by researchers from Imperial College London, University College London, Queen Mary University of London, the University of East Anglia and St Mark’s Hospital, the University of Oxford. The study was funded by the Medical Research Council, the National Institute for Health Research, and Cancer Research UK.
Ends
MRC Press Office
press.office@headoffice.mrc.ac.uk
020 7637 6011
